Vitafoods Europe
OmniActive to Launch New Ingredients in EU Regions
The company is introducing new botanicals for sleep and mood support, and has achieved non-novel food status for Lutemax 2020.
Photo: OmniActive
Booth 4J27
OmniActive Health Technologies will be launching several ingredients in key EU regions at Vitafoods Europe, including two new specialty ingredients, Sleeproot and Zenroot.
Sleeproot is a valerian extract evidenced to support sleep duration starting from day one of supplementation. A randomized, placebo-controlled study published in Advances in Complementary & Alternative Medicine found that daily supplementation also led to improvements in the time it takes to fall asleep by day 3.
The extract is standardized to 2% valerenic acid, while most typical valerian products range in concentrations from 0.4% to 0.8%. The high potency, with no safety related concerns, allows for lower dosing and greater formulation flexibility. Sleeproot can be used for traditional formats like tablets and capsules, gummies, and ready-to-mix powders.
OmniActive will also launch Zenroot, a low-dose, root-only ashwagandha extract standardized to 1.5% withanolides using the USP method for consistent quality and reliability. It is formulated for 125 mg daily doses, and is flexible enough for gummies and beverages.
Zenroot is clinically studied to reduce feelings of occasional stress and anxiety, and support improvements in mood and sleep quality; these findings are expected to be published later this year.
“Bringing high-quality, clinically-supported ingredients like Sleeproot and Zenroot to Europe is a key priority and further deepens our presence in this market,” said Kratika Gupta, senior vice president of global marketing. “These launches will allow us to meet consumer demand for holistic mental wellness while enabling our business partners to innovate confidently in one of the world’s most forward-looking markets.”
Lutemax 2020 Granted Non-Novel Status in EU
OmniActive’s flagship ingredient, Lutemax 2020, a proprietary blend of lutein, zeaxanthin, and meso-zeaxanthin, has been recognized by the EU as non-novel for use in food supplements. This affirms the ingredient’s history of safe use, and paves the way for broader commercialization across the European market.
“This achievement reflects our commitment to rigorous compliance and scientific integrity,” said Arpita Tamhankar, director of regulatory affairs at OmniActive. “The non-novel status reaffirms Lutemax 2020’s established safety profile and reinforces its position a leading macular carotenoid ingredient for European markets.”
The blend of carotenoids is sourced from marigold flowers, delivering them in a 5:1 ratio, like what is found in the diet. It has been supported in 10 peer-reviewed clinical studies for applications in visual performance, blue light protection, and cognitive health.
“European customers can now confidently incorporate Lutemax 2020 into their products knowing it meets safety and transparency standards,” said Akhil Bajaj, divisional vice president of category management.
